CUR5g, a novel autophagy inhibitor, exhibits potent synergistic anticancer effects with cisplatin against non-small-cell lung cancer

Jingxuan Chen, Yunpeng Shen, Bowen Wu, Peichang Yang, Gangchun Sun, Xiaoting Liu, Pengfei Qiang, Yamei Gao, Fangfang Sha, Zirui Li and Lu Zhang

© The Author(s) 2022

INTRODUCTION

Lung cancer, with an estimated 2.2 million new cancer cases and 1.8 million deaths in 2020, remains the leading cause of cancer deaths [1]. The overwhelming majority (approximately 85%) of lung cancer is non-small cell lung cancer (NSCLC), and more than 70% of cases are diagnosed at an advanced stage when surgery is not appropriate [2]. Even with successful surgical resection in early stage, a considerable number of patients develop local or distant recurrences [3]. Cisplatin-based combination have been recommended as the first-line treatments for NSCLC, but numerous undesirable effects including chemotherapy resistance and adverse reactions are still the vital bottlenecks which limit its curative efficiency in most NSCLC patients. Thus, it is of great importance to identify novel low-toxic agents that increase the sensitivity of NSCLC cells to cisplatin.

Autophagy supplies the demand for NSCLC cells survival under unfavorable conditions and helps them cope with threatening stressors, which has been considered as an important mechanism of chemotherapy resistance [4]. High levels of basal autophagy are prevalent in cisplatin-resistant cancer cells and are thought to confer survival benefits [4]. Increasing number of studies have demonstrated that block of autophagy effectively increased the sensitivity of NSCLC cells to cisplatin [5–7], thereby providing a reasonable basis for the combined use of autophagy inhibitors and cisplatin for NSCLC treatment.

Currently, chloroquine (CQ) and its derivative hydroxychloroquine (HCQ), which inhibit autophagosome degradation by limiting the acidification of lysosomes, are still the only clinically available autophagy inhibitors [8]. Several studies have shown that CQ or HCQ enhanced cisplatin-induced cytotoxicity in NSCLC cells [7, 9, 10], but there is still a lack of clinical data on the combination of CQ or HCQ and cisplatin in the treatment of NSCLC. Importantly, clinical studies showed that even at a high dose of 1200 mg/d, HCQ produces only modest autophagy inhibition in human tissues [11]. Although generally considered to be well tolerated in vivo, several side effects of HCQ and CQ have been reported, including gastrointestinal discomfort, retinopathy, cardiomyopathy, and so on [12]. The lack of potency in inhibiting autophagy and off-target toxicity of CQ and HCQ create a demand for the discovery of novel autophagy inhibitors that specifically target autophagy in cancer cells without interfering with other cellular processes and concurrently minimizing autophagy dysfunction in normal cells.
The vast majority of newly discovered autophagy inhibitors that inhibit tumor growth, are natural products or their derivatives by structural modifications, such as oblongifolin C, liensine, elaophyllin, hederaegenin, alpha-hederin, CA-5f, etc. [13-18]. Curcumin has been proved to be a naturally occurring autophagy modulator with anti-tumor activity, however, its reduced bioavailability in vivo severely limits its clinical implication [19]. Curcumin derivatization is an effective strategy to overcome such obstacle. More excitingly, some curcumin derivatives as newly identified autophagy inhibitors have been shown to selectively inhibit NSCLC without obvious cytotoxic influences on normal cells [18, 20].

In this study, we found that (3E,5E)-1-methyl-3-(4-hydroxybenzylidene)-5-(3-indolymethylene)-piperidine-4-one (CUR5g), a curcumin derivative, selectively induced autophagosome accumulation in cancer cells by blocking autophagosome-lysosome fusion. CUR5g blocked the recruitment of STX17 to autophagosomes via a UVRAG-dependent mechanism, resulting in the inability of autophagosomes to fuse with lysosomes. CUR5g exhibited effectively anti-proliferative effects against NSCLC A549 cells. More excitingly, the combination use of CUR5g dramatically improved the anticancer effect of cisplatin against A549 cells both in vitro and in vivo.

RESULTS
CUR5g selectively induces autophagosome accumulation in cancer cells
This study used U87 cells with stable expression of GFP-LC3B fusion protein to screen various curcumin analogs to find new small-molecule inhibitors of autophagy. Among these analogs, CUR5g (Fig. 1A) induced extensive cytoplasmic vacuolization, and GFP-LC3B reporter (Fig.2D). The punctuate pattern outlining autophagosomes (Figs. 1B and S1), suggesting that CUR5g might regulate autophagy. As revealed by WB assay, CUR5g up-regulated LC3B-II and sequestosome 1 (SQSTM1) levels time- and dose-dependently (Fig. 1C). This increase was not the result of enhanced transcription, as mRNA expression of SQSTM1 and LC3B were not increased within CUR5g-exposed cells (Fig. 1D), suggesting that CUR5g might block autophagic flux rather than increase autophagosome formation.

Excitingly, CUR5g also induced SQSTM1 and LC3B-II accumulation in other human cancer cells (Fig. S2), but not in normal cells (Fig. S3). The punctuate distribution of GFP-LC3B was significantly increased in CUR5g-treated A549 cells (Fig. 1E). Following 24-h exposure to 10 μM CUR5g, numerous autophagosomes were observed in A549 cells, but much fewer in untreated controls (Fig. 1F). Based on these observations, CUR5g were selected for subsequent experiments.

CUR5g causes a late-stage block of autophagy by suppressing the formation of autophagosome with lysosome
Exposure to 3-MA, the autophagosome formation inhibitor, did not eliminate CUR5g-induced SQSTM1 and LC3B-II accumulation (Fig. 2A). Treatment of A549 cells with CUR5g and the late-stage autophagy inhibitor CQ showed no effect on further increasing LC3B-II relative to simply CQ (Fig. 2B). CUR5g further induced LC3B-II accumulation within A549 cells under the nutrient deficient state compared with those cells maintained in nutrient adequate medium (Fig. 2C), indicating that CUR5g causes a late-stage block of autophagy.

Congruently, CUR5g increased the GFP-LC3 punctum number (autophagosomes, yellow), but not GFP RFP punctum number (autolysosomes, red), in HEK293T cells stably expressing RFP-GFP reporter (Fig. 2D).

Additionally, CUR5g's role in major proteins levels involved in autophagosome formation was analyzed, namely, the mechanistic

![Fig. 1 CUR5g modulates autophagy in A549 cells. A The chemical structure of CUR5g. The molecular formula of this compound is C_{24}H_{22}N_{2}O_{3}, and its molecular weight is 344.41 g/mol. B Representative microscopy photographs of A549 cells treated with various doses (0–40 μM) of CUR5g for 3–24 h. Scale bar = 40 μm. C Western blot analysis of LC3B-II and SQSTM1 levels in A549 cells treated with various doses (0–40 μM) of CUR5g for 24 h, or in the cells treated with 10 μM CUR5g for 0–24 h. GAPDH was used as a loading control. (n = 3; *p < 0.05, **p < 0.01 vs. 0). D qRT-PCR analysis of LC3B and SQSTM1 mRNA levels. E Representative fluorescence photographs of GFP-LC3B puncta in A549 cells treated with various doses (0–40 μM) of CUR5g for 24 h. Scale bar = 10 μm. Nuclei were stained with DAPI. Histogram shows quantification of the percentage of cells with GFP-LC3B puncta. (n = 3; *p < 0.05, **p < 0.01 vs. 0). F Representative transmission electron micrographs of A549 cells treated with DMSO or 10 μM CUR5g for 24 h. Boxed areas at left are enlarged at right. Scale bar = 1 μm.](Image)
target of rapamycin kinase (mTOR) and its substrate RPS6kB1, ATG14-like protein (Atg14L), BECN1, phosphatidylinositol 3-kinase catalytic subunit type 3 (PIK3C3), UV radiation resistance-associated gene (UVRAG), phosphoinositide 3-kinase regulatory subunit 4 (PIK3R4), as well as ATG5. Except for the significant reduction in UVRAG levels, the levels of other proteins in CUR5g-treated cells were not statistically different from control cells (Fig. 2E), further ruling out the possibility that CUR5g increases autophagy initiation.

The inhibition of autophagy can be induced by impaired autophagosome degradation or blocking of autophagosome-lysosome fusion. To clarify how CUR5g works, we detected the LC3B-LysoTracker Red colocalization within U87 cells. The overlap of LC3B-GFP signals with LysoTracker Red signals was observed in
EBSS-incubated cells, rather than CUR5g-treated counterparts (Fig. 2F), indicating that CUR5g inhibits the fusion of autophagosomes and lysosomes. Notably, CUR5g did not reduce acid-dependent LysoTracker Red signals, unlike CQ, which accumulates within and alkalinizing the lysosome, suggesting that CUR5g does not block lysosome acidification. In parallel, LC3B puncta and lysosomal-associated membrane protein 1 (LAMP1, the lysosomal marker) were dramatically separated within CUR5G-treated cells, a phenomenon close to CQ-treated cells in a less pronounced manner (Fig. 2G), confirming that CUR5g blocks autophagosome-lysosome fusion.

CUR5g does not affect the lysosomal proteolytic function and cytoskeleton

We examined the effect of CUR5g on lysosomal pH with the use of LysoTracker Red and acridine orange (AO) to further clarify whether CUR5g affects lysosomal function. We found that CUR5g did not attenuate red fluorescence in the above two dyes (Fig. 3A), indicating that CUR5g did not induce lysosomal alkalinization. CUR5g did not suppress the activities of lysosomal proteases, including acid phosphatase (ACP), CTSB, and CTSD (Fig. 3B–D). In parallel, according to the WB assay, CUR5g had no effect on lysosomal marker LAMP1 expression, nor the conversions of proCTSB and proCTSD to mature cathepsins (Fig. 3E), supporting the notion that CUR5g does not disrupt lysosomal proteolytic function. Moreover, CUR5g treatment did not change the distribution of F-actin, vinculin, and β-tubulin (Fig. 3F). Vinculin and β-tubulin expression in CUR5g-treated cells were not significantly different from untreated cells (Fig. 3G), suggesting that CUR5g does not affect the cytoskeleton.

Overexpression of UVRAG reverses CUR5g-induced autophagosome accumulation

In addition to being a key component in autophagosome formation, UVRAG is also thought to be necessary for autophagosome-lysosome fusion [24]. The fact that UVRAG levels remarkably decreased within CUR5g-exposed cells (Figs. 2E and S5), making us investigate whether the failure of autophagosome-lysosome fusion is due to UVRAG downregulation. We found that...
in UVRAG overexpressing cells, CUR5g failed to induce the accumulation LC3B-II and SQSTM1, increase the number of GFP^+^RFP^+^ puncta, or prevent the recruitment of STX17 to autophagosomes (Fig. 5A–C). Overexpression of UVRAG did not prevent CUR5g-induced SQSTM1 and LC3B-II accumulation within STX17 knockdown cells (Fig. 5D). These results collectively demonstrated that CUR5g inhibits STX17 targeting to autophagosomes by down-regulating UVRAG.

The molecular modeling and docking studies predicted that CUR5g appears to bind preferably to the region 270–442 of UVRAG (Fig. S6) which was sufficient for interaction with VPS16 [25]. Efficient binding to VPS16 is necessary for UVRAG to fully facilitate autophagosome-endosome/lysosome fusion [25], raising the possibility that CUR5g might weaken the interaction between UVRAG and VPS16 and therefore impairs the maturation of the autophagosome. Supporting this notion, we found that CUR5g weakened UVRAG-VPS16 interaction by immunofluorescence observation and coimmunoprecipitation analysis (Fig. S7).

**CUR5g exerts anticancer effects on A549 cells**

A549 cell number slightly decreased after treatment with 10 µM CUR5g, while CUR5g at 20 µM decreased the number of A549 cells significantly (Fig. 6A), suggesting that CUR5g showed more selective autophagy inhibitory effects and cytotoxic activity against NSCLC cells than in A549 cells (Fig. 5A–C). More excitingly, at the concentration below or equal to 50 µM, CUR5g did not induce a statistically significant reduction in UVRAG levels (Fig. S9C), and the interaction between UVRAG and VPS16 is not significantly affected by CUR5g (Fig. S9D), suggesting that A549 cells might be more sensitive to CUR5g because they exhibit lower basal levels of UVRAG. These results at least partially explained why CUR5g showed more selective autophagy inhibitory effects and cytotoxic activity against NSCLC cells than normal HUVECs. In addition, 10 µM CUR5g almost completely suppressed the colony formation in A549 cells (Fig. 6C). Upon CUR5g treatment, G0/G1-phase cell proportion declined, whereas S phase proportion elevated (Fig. 6D), suggesting that CUR5g promoted cell cycle arrest of A549 cells at S phase.

CUR5g at 10 µM almost completely inhibited colony formation, promoting us to examine whether CUR5g affects the mobility of A549 cells. As revealed by a scratch assay, CUR5g significantly inhibited A549 cell migration (Fig. 6E). After treatment with CUR5g, Annexin V-positive cell proportion (Fig. 6F) and levels of cleaved PARP1 or cleaved Caspase-3 did not increase (Fig. 6G), nor did the activity of lactic acid dehydrogenase (Fig. 6H), suggesting that CUR5g did not induce apoptosis and necrosis of A549 cells.

![Figure 4](https://example.com/fig4.png)

**Fig. 4 CUR5g blocks incorporation of STX17 on autophagosomes.** A Western blot analysis of STX17, SNAP29, and VAMP8 levels in A549 cells treated with CUR5g (10 µM) for 0–24 h. GAPDH was used as a loading control. B, C Representative fluorescence images of the colocalization of LC3B (green) and STX17 (red) (B) or LC3B (green) and SNAP29 (red) (C). Nuclei were stained with DAPI. The line-scanned profiles show the distribution of fluorescence for each channel in the white line in the corresponding confocal images. Scale bar = 10 µm.
Similarly, CUR5g made no difference to intracellular and mitochondrial ROS, nor the MMP levels (Fig. S10 and S11). CUR5g exhibits potent synergistic anticancer effects with cisplatin on A549 cells and inhibits autophagic flux in vivo. We further tested whether CUR5g could synergize with cisplatin to exhibit stronger anticancer activity against NSCLC. Different from the cells exposed to CUR5g or cisplatin alone, the number of A549 cells co-treated with CUR5g and cisplatin displayed a rapid decrease, and this trend maintained until the end of the experiment (Fig. 7A). Likewise, data from colony formation assay and wound-healing assay showed that CUR5g enhanced cisplatin’s anticancer activity in A549 cells (Fig. 7B, C). Moreover, we compared the effectiveness of CUR5g with other three autophagy regulators including curcumin, CQ, and CA-5f in combination with cisplatin. At the same concentration of 10 µM, CUR5g/cisplatin combination induced more effective synergistic cytotoxicity to A549 cells than the combination of cisplatin with curcumin or CA-5f. The effectiveness of 10 µM CUR5g combined with cisplatin is similar to 30 µM CQ combined with cisplatin (Fig. S12).

To explore whether the combination of CUR5g and cisplatin serves a similar function in vivo, a xenograft nude mouse model of NSCLC was established by subcutaneously injecting A549 cells. CUR5g alone or combined with cisplatin showed well tolerance in nude mice, and abnormal physical signs were not reported in the whole procedure. Differences in average body weight (BW) among
all treatments were not significant (Fig. S13). No signs of mortality or macroscopic abnormalities in the organs were discovered, and no obvious pathological alterations were observed in the major organs (Fig. S14). The size and weight of the dissected tumors in the CUR5g and cisplatin combination group remarkably decreased compared with the remaining groups (Fig. 7D, E). As expected, CUR5g or cisplatin alone retarded the growth of xenografted tumors, whereas the combination treatment almost completely inhibited tumor growth (Fig. 7F), demonstrating that CUR5g potently enhanced cisplatin’s anticancer activity in A549 cells in vitro as well as in vivo. Consistent with in vitro data, as revealed by WB assay, CUR5g increased LC3B-II and SQSTM1 levels within tumor tissues (Fig. 7G). The level of LC3B-II in CUR5g plus cisplatin group significantly increased relative to cisplatin group (Fig. 7G). Immunofluorescence staining showed a significant increase of punctate LC3B and SQSTM1 signals in tumor tissues obtained from CUR5g-treated group as relative to control (Fig. 7H, I). CUR5g synergistically promoted the effect of cisplatin on LC3B accumulation in tumors (Fig. 7H, I). In conclusion, the above findings suggested that CUR5g promoted the cisplatin sensitivity of A549 cells by inhibiting autophagic flux.

**DISCUSSION**

Countless evidence has demonstrated that autophagy helps NSCLC to resist various chemotherapeutic drugs, and thus has emerged as an attractive target to overcome drug resistance [16, 17, 26]. A growing number of clinical trials have been proposed or are undergoing to evaluate the anticancer effect of autophagy inhibitors combined with chemotherapeutic drugs (http://clinicaltrials.gov). However, the vast majority of autophagy inhibitors identified so far, especially CQ and its derivative HCQ, actually disrupt lysosomal and/or possible non-lysosomal events different from autophagy [27]. In fact, the anticancer therapeutic effect of HCQ and CQ may be achieved through modulating autophagy-independent machinery, as evidenced by the unsatisfactory inhibitory effect of high-dose HCQ on autophagy in clinical trials [11, 27]. Thus, the discovery of more selective and specific autophagy inhibitors is a prerequisite for preclinical validation studies.

This work discovered that CUR5g was the new autophagy inhibitor that can affect autophagy within diverse cancer cell types, but not within non-tumor cells. CUR5g inhibits late autophagy by suppressing autophagosome-lysosome fusion. A wide majority of late-stage autophagy inhibitors are actually lysosomal inhibitors, which alkalinize intralysosomal pH or/and impair the lysosomal function, thereby resulting defect in lysosomal degradation of autophagosomes. One of the limitations of these lysosome inhibitors is the lack of specificity to target autophagy, which may affect other metabolic pathways and cause lysosomal storage disease [28, 29]. CUR5g did not influence lysosomal acidification and hydrolytic function, nor did it affect...
Fig. 7  CUR5g exhibits synergistic anticancer effects with cisplatin and inhibits autophagic flux in vivo. A Cell number was monitored over 96 h in a real-time manner using an xCELLigence RTCA S16 System. DMSO, CUR5g (10 μM), cisplatin (30 μM), or CUR5g (10 μM) plus cisplatin (30 μM) was added after the cells were seeded into the plates for 24 h. B Representative images of colony formation assay of A549 cells treated with DMSO, CUR5g (10 μM), cisplatin (30 μM), or CUR5g (10 μM) plus cisplatin (30 μM) for 12 days. Histogram shows the relative colony survival. (n = 3; **p < 0.01 vs. Control, #p < 0.05 vs. cisplatin). C The effect of DMSO, CUR5g (10 μM), cisplatin (30 μM), or CUR5g (10 μM) plus cisplatin (30 μM) on the migratory potential of A549 cells was analyzed through a wound-healing assay. Microscopy photographs were taken after treatment for 0, 24, or 48 h, respectively. Scale bar = 100 μm. Histogram showed the wound closure rate. (n = 3; *p < 0.05; **p < 0.01 vs. control, #p < 0.05 vs. cisplatin). D Images show all the animals and tumors in the experiments. E Tumor weight was measured on the day of sacrifice. (Each group mice n = 4–5; *p < 0.05 vs. control, #p < 0.05 vs. cisplatin). F Tumor volume were recorded every 2 days for up to 15 days. (Each group mice n = 4–5; *p < 0.05 vs. control, #p < 0.05 vs. cisplatin). G Western blot analysis of LC3B-II and SQSTM1 in tumor tissues. 3 tumor tissues were randomly selected from each group for analysis. GAPDH was used as a loading control. Scattergram shows the densitometric analysis of LC3B-II and SQSTM1 in tumor tissues. H, I Representative fluorescence images of LC3B (H) or SQSTM1 (I) in tumor sections. Nuclei were stained with DAPI. Scale bar = 80 μm.
lysosome quantity, indicating that this small-molecule compound is a non-lysosomal targeting inhibitor. The trafficking of autophagosomes and their fusion with lysosomes are mainly dependent on cytoskeletal systems including actin and microtubules [30]. CUR5g had no significant effect on cytoskeleton of A549 cells, as indicated by unchanged reticular or fascicular distribution of F-actin and β-tubulin, and vinculin and β-tubulin expression was not significantly different. Assembly of the SNARE complex is another critical step in membrane fusion. During autophagy, STX17 will be recruited into the complete autophagosomes, followed by interaction with SNAP29 as well as endosomal/lysosomal VAMP8 for forming the SNARE complex, thus providing the energy necessary in autophagosome-lysosome fusion [21]. CUR5g impeded STX17 translocation onto autophagosomes by down-regulating UVRAG, thereby rendering autophagosomes “fusion failure.” A previous study indicated that UVRAG not only regulates the formation of autophagosomes but also facilitates their fusion with lysosomes [25]. However, later studies showed that UVRAG is mainly involved in lysosomal degradation, while it is dispensable for autophagosome-lysosome fusion, and thus it may regulate autophagy indirectly [24, 31]. Although the precise role of UVRAG in autophagosome-lysosome fusion is controversial, our results showed that CUR5g-induced UVRAG reduction is the main reason that hinders STX17 loading onto autophagosomes. As mentioned above, routinely-used late-stage autophagy inhibitors such as 3-MA and wortmannin are non-specific as they suppress all phosphatidylinositol 3-kinase-associated pathways, leading to a plethora of side effects. Our results showed that CUR5g interfered with the recruitment of STX17 onto autophagosomes thereby hindering the maturation of autophagosomes. Blockade of STX17 is more specific than use of lysosomal inhibitors in inhibiting autophagic flux [32], such observations support the idea that using CUR5g, a small-molecule compound blocks the incorporation of STX17 onto autophagosomes, might represent a cleaner way to inhibit autophagosome degradation.

More excitingly, CUR5g selectively induced autophagosome accumulation within tumor cells, rather than healthy cells, which might avoid undesirable side effects. Supporting this notion, CUR5g showed no obvious toxicity to normal HUVECs in vitro or mice in vivo. CUR5g alone did not induce apoptosis and necrosis of A549 cells, but significantly inhibited the mobility and colony formation of A549 cells. In animals, the anticancer effect of CUR5g was limited, while its combination with cisplatin almost completely inhibited lung adenocarcinoma growth without induction of the body weight loss and histological changes of vital organs. In A549 xenographs, CUR5g administration markedly promoted LC3B-II and SQSTM1 levels by immunofluorescence staining and western blot analysis, confirming the efficiency of CUR5g in inhibiting autophagy of lung adenocarcinoma in vivo. However, whether there is a link between CUR5g-induced S phase arrest and autophagy inhibition remains unknown. Previous studies provided some insight into this concern. Silencing of autophagy-related ATG5 arrested cells in S phase [33], a phenotype similar to the cells that were treated with autophagy inhibitors CQ [34], suggesting a possibility that CUR5g-induced autophagy inhibition might contribute to S phase arrest in A549 cells. It has been reported that cisplatin facilitated cell cycle arrest in lung cancer cells [35, 36]. A further S phase arrest induced by CUR5g may make the damage exceed the threshold that cells can bear, which may be another potential reason for the synergy of cisplatin and CUR5g. A combination treatment of the autophagy inhibitor 3-MA and cisplatin elevated S phase cell proportion as well as apoptosis rate [37]. Such observations support this possibility. Whether and how S phase arrest is associated with CUR5g-induced autophagy inhibition and synergistic effect with cisplatin should be further explored.

In summary, this work identifies CUR5g as the specific late autophagy inhibitor without affecting other cellular processes (lysosomal acidification and hydrolysis function, cytoskeleton, Rab7, and ROS). Our study provides a novel tool for selectively inhibiting autophagy in cancer cells and is a potential candidate to develop for the treatment of NSCLC in conjunction with cisplatin. We will explore the direct targets of CUR5g combined with other first-line chemotherapy regimens in our future study.

**METHODS**

A series of curcumin analogs, including CUR5g (>99% purity as determined through high-performance liquid chromatography), were previously synthesized at our lab. All tested analogs were subject to dissolution within dimethyl sulfoxide (DMSO) for preparing the stock solution (10 mM) diluted in different doses prior to application. This work obtained fetal bovine serum (FBS; SH30084.03) in HyClone (Logan, Utah, USA), RPMI 1640 medium (11875101), and DMEM medium (11995065) in Gibco (Grand Island, NY, USA). Trypsin (A003702), DMSO (A100231-0500), bis-acrylamide (A600025-0250), tris (A600194-0500), ammonium persulfate (A600072-0100) and sodium dodecyl sulfate (SDS; A100227) were provided by Shanghai Sangon Biotech (Shanghai, China). Protease inhibitor cocktail (P8340), Earle’s balanced salt solution (EBSS; E2888), chlortetracycline (CO; C6628), 3-methyladenine (3-MA; M9281), acridine orange (AO; 235474), thiazolyl blue tetrazolium bromide (MT; M2128), curcumin (C1386) and 4,6-diamidino-2-phenylindole dihydrochloride (DAPI, D8417) were provided by Sigma-Aldrich (St. Louis, MI, USA). Mitosox™ red mitochondrial superoxide indicator (M36008), Premo™ autophagy sensor LC3B-GFP (BacMam 2.0; P36235), Lipofectamine™ 2000 CD Transfection Reagent (12566014) and Lysotracker Red DND (L7528) were provided by Invitrogen (Carlsbad, CA, USA). This work acquired DY fde phallidin conjugates in US Everbright, Inc. (Suzhou, China), whereas FITC Annexin V Apoptosis Detection Kit I (556547) in BD Biosciences (NJ, USA). Meanwhile, the present study acquired the primary antibody against PARP1 (AP102), Lyso-Tracker Red (C1046), JC-1 probe (C2006), Ad-GFP-LC3B (C3006), Reactive Oxygen Species Assay Kit (S0033), ACP assay kit (P0326), apoptosis inducers kit (C0005), PI (C1052), BeyoMag Anti-Flag Magnetic Beads (P2115) and polycrylene (C03511) in Beyotime Biotechnology (Shanghai, China). GoldView I nucleic acid dye (G8140) and bovine serum albumin (BSA, A8020) were provided by Solarbio (Beijing, China). Meanwhile, this work acquired Cathepsin B (K140) and D (K143) activity fluorometric assay kits in Biovision (CA, USA). This work acquired lactate dehydrogenase assay kit (A0201-1) in NanJing JianCheng (Nanjing, China), whereas RPure total RNA kit (R4011-02) in Magen (Guangzhou, China), whereas 2x Taq Master Mix (Dye Plus; P112), Ace® qPCR SYBR® Green Master Mix (Q111), and HisScip® II Q RT Supermix for qPCR (R223-01) in Vazyme Biotechnology (Beijing, China). 4% paraformaldehyde (MA0192) was purchased from meilunbio (Dalian, China), pHAGE-CMV-MCS-IRE-S-Green1 vectors (P4867) were obtained from miaoWang (Wuhan, China), pLKO.1 vectors (VT1792) were obtained from YouBio (Guangzhou, China). PMID.G (12259) and PsPAX2 (12260) were purchased from addgene (Cambridge, MA, USA). Crystal violet (1199) was provided by DAMAO CHEMICAL REAGENT FACTORY (Tianjin, China). In the meantime, this work purchased HeLa and Eosin Staining Kit (G1005) in Servicebio (Wuhan, China), Anti-GAPDH (G9545), anti-SQSTM1 (P0067), anti-LC3B (L7543), anti-Pi3Kγ4 (HPA036032), anti-CTSB (SAB1405676), anti-CTSD (SAB21006553), anti-mTOR (T2949), anti-p-mTOR (SAB4504476), anti-Pi3K3C (V9764), and anti-UVRAG (SAB4200005) primary antibodies were provided by Sigma-Aldrich (St. Louis, Montana, USA), Anti-VP53 (A34755), anti-phospho-ERK (9206), anti-Atg14L (96752), and anti-LAMP1 (15665) and anti-ATG5 (12994) primary antibodies were provided by Cell Signaling Technology (MA, USA). Anti-vinculin (26520-1-AP) and anti-VPS16 (17776-1-AP) primary antibodies were provided by Wuhan Sanying Biotech (Wuhan, China), Anti-β-tubulin (A01030) primary antibody was provided by Abdkine (California, USA), Anti-Beclin 1 (AP6020) primary antibody was provided by BioWorld (MN, USA). Anti-Inhibitor 1 (ab24568) and anti-AMPK (ab9158) and anti-SNAP29 (ab118151) primary antibodies, and anti-Alexa Fluor® 647 goat anti-rabbit IgG secondary antibody (150079) were provided by Abcam (Cambridge, MA, USA). Anti-IRDye® 680RD goat anti-mouse (926-68070), anti-IRDye® 680RD goat anti-rabbit (926-68071), anti-IRDye® 800CW goat anti-mouse.
(925-32210) and anti-IRDye® 800CW goat anti-rabbit (925-32211) secondary antibodies were provided by Li-Cor Biosciences (NE, USA). Anti-Alexa Fluor® 488 goat anti-mouse IgG (ZF-0512) and anti-Alexa Fluor® 488 goat anti-rabbit IgG (ZF-0511) secondary antibodies were provided by Beijing ZSGB-BIO (Beijing, China). Cisplatin (HY-17394) and baflofin A1 were purchased from MedChemExpress (NJ, USA). The plasmid Rab7-Q67L and Rab7-T22N were kindly provided by Dr. Youli Jian (State Key Laboratory of Molecular and Developmental Biology, Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing, China).

**Cell culture.** This work obtained A549 (SCSP-503) and MCF-7 (SCSP-531) cell lines in Cell Bank of Chinese Academy of Sciences (http://www.cellbank.org.cn), whereas Adryanin-resistant MCF-7 breast cancer (Beijing Key Laboratory of Cancer, CNIC, Beijing, China) cells were all within RPMI 1640 medium, whereas U87, HEK293T, HepG2, MCF-7, and MCDB-131 medium (Sigma-Aldrich, M8537) that contained 70 ng/ml α-interferon (α-IFN) was utilized for band scanning. For quantification, Odyssey Application Software was used to determine the band intensity.

**Quantitative real-time PCR (qRT-PCR).** This work collected total RNA and prepared it into cDNA according to specific protocols. The LC3B and SQSTM1 mRNA expression was analyzed by 2^-ΔΔCt approach, with GAPDH being a normalization reference. The corresponding primers: LC3B-F: 5'-TACGACTTGTGTAGCGTCTGC-3', LC3B-R: 5'-GTGTCCGTATTGTTCGTTTTTG-3'; SQSTM1-F: 5'-TACCAACCGTCTTCAAGGAGG-3', SQSTM1-R: 5'-H15ST GTTTTACCCCTCC-3', GAPDH-F: 5'-AATGAGACCTTACAGAAC-3', GAPDH-R: 5'-TCCAGACAGTCTACACGCCG-3'.

**Transmission electron microscopy.** After growing of A549 cells till about 80% density within the 100-mm dishes, cells were subject to treatment using DMSO or CUR5g (10 μM) for 24 h. After fixation with 2.5% glutaraldehyde, dehydration using the graded ethanol series before being embedded in epoxy resin and sectioning. Cells were then stained by aqueous uranyl acetate and later by lead citrate, finally the JEM-1230 transmission electron microscopy (JEOL Co., Ltd., Japan) was utilized for photographing of ultrathin sections.

**Immunofluorescence (IF) analysis and confocal microscopy.** After growing of U87 cells till around 80% confluency within the 14-mm round-glass coverslips, cells were transfected with Ad-GFP-LC3B, followed by 24-h treatment using DMSO, CUR5g (10 μM) or 6-h incubation with IQ (30 μM) or EBSS. Afterwards, cells were subject to fixation using 4% paraformaldehyde (PFA), blocking with 5% BSA within PBS that contained Tween-20 (PBST), labeling using corresponding primary antibodies under 4 °C overnight, and 30-min incubation using secondary antibodies under 37 °C. DAPI was added for nuclear counter-staining. Finally, the cells were photographed with the confocal laser-scanning microscope (Olympus FLUOVIEW FV3000). Fluorescence distribution between white lines in the corresponding images was conducted by ImageJ software (National Institutes of Health).

AO, LysoTracker Red, and F-actin staining. After growing A549 cells till around 80% confluency within 24-well plates, cells were exposed to DMSO or CUR5g (10 μM) at various times, followed by 10-min staining using 5 μg/mL phalloidin for 37 °C or 15-min staining using 1 mM Lysotracker Red under 37 °C, respectively. Following the manufacturer’s instructions, after 15-min fixing in 4% PFA, cell staining with phallolidin conjugates (200 μL) was conducted for detecting F-actin. Nuclei were counterstained with DAPI.

**Detection of ACP, CTSD, and CTSB enzymatic activities.** Commercially available assay kits were used to detect ACP, CTSD, and CTSB enzymatic activities in line with specific instructions. The ACP activities were measured as the absorbance with the Epoch TM spectrophotometer (BioTek Instruments) at 405 nm. For CTSD, fluorescence was detected at the emission and excitation wavelengths of 505 and 400 nm, separately, whereas 460 and 328 nm separately for CTSB using a microplate reader (PerkinElmer EnSpire).

**Construction and identification of overexpression or shRNA lentiviral vectors.** The sequences used for UVRAG overexpression were shown below: F'-GGCGACCGGGACCGAGATATCGGCTCGTTGCTG-3', R'-CCGGTCGACCTTATCGGAAATCTCGGGCGAATTTCTCGGATATTGGATCG-3'. Each sequence was cloned in MuI (and Xhol I-cleaved pHAGE-MV-ICS-ZGreen1 vectors. The shRNA sequences targeting STX1 were shown below: F'-CGCCGCAGCATTAATCGGGAAATCTCGGGCGAATTTCTCGGATATTGGATCG-3'; R'-AACAAAGATTCCAATTCGCGAATTTCTCGGGATATTTGCCTGGAC-3'. Each sequence was cloned in AgeI- and EcoR I-cleaved pLKO1 vectors. Calcium chloride was utilized to prepare DH5α competent cells for subsequent transfection. PCR assay was conducted to select positive clones, which were sent to Sangon Biotech for sequencing.

**Lentivirus collection and transfection.** Target plasmid (1 μg) was co-transfected with 250 ng PMD2.G and 750 ng PpPAX2 into HEK293T cells. At 48 h later, medium containing lentivirus was harvested for 30-min centrifugation at 6000 rpm to collect supernatants, which were then filtered using the 0.45-µM filter (210910, BIOFIL), followed by 2-h centrifugation at 20,000 rpm and 4 °C. After growing of A549 cells till about 60% confluency within the 6-well plates, cells were subject to infection using lentivirus suspension that contained 4 μg/ml polybrene. At 4 h later, polybrene was diluted with freshly prepared medium (1 ml). At 48-h post-transfection, fresh medium that contained 4 μg/ml puroycin was added to incubate cells for another 24 h. Overexpression or knockdown efficiency was identified by PR-PCR and WB assays.

**Cell viability assay.** This work inoculated A549 cells in E-Plate 16-well plates, followed by treatment using DMSO, a series of concentrations of CUR5g (1–20 μM), cisplatin (30 μM), CUR5g (10 μM) and cisplatin (30 μM). The cells were continuously monitored for 96 h with xCellLigence RTCA S16 System (ACEA Biosciences). The changes in cell-electrode impedance were converted to cell index representing cell viability with RTCA S16 Software (version 1.0). In addition, MITT assay was carried out to analyze cell viability. After inoculation of cells into the 96-well plates, they were subject to treatment using DMSO or a series of concentrations of CUR5g (1–20 μM). After discarding the original medium, freshly prepared medium (100 μL) containing MITT solution was introduced into all wells, followed by 4-h incubation. The microplate reader (Tecan Spark, Switzerland) was employed for measuring cell viability at 490 nm.

**Colony formation assay.** After inoculation of A549 cells (3 × 10^4) in six-well plates, DMSO, CUR5g (10 μM), cisplatin (30 μM), CUR5g (10 μM), and cisplatin (30 μM) were added every 2 days for 12 days, followed by 4% PFA fixation and 0.5% crystal violet staining for colony visualization.

**Cell cycle analysis.** After growing to ~60% density within the 100-mm dishes, A549 cells were treated with 12/24-h DMSO or CUR5g (10 μM), respectively. After treatment, they were collected and immersed in cold 70% ethanol for 4 h, followed by centrifuging at 1000 g for 5 min and staining with PI for a 30-min period under 37 °C. At last, flow cytometry (FCM, BD FACSCalibur, Franklin Lakes, NJ, USA) was performed for cell analysis.
Scratch assay. After growing of A549 cells till density within the 24-well plates, scratches were made in the well center using the sterile pipette tip. Cells were later washed and treated by DMSO, CUR5g (10 μM), cisplatin (30 μM), CUR5g (10 μM), and cisplatin (30 μM). Images were made immediately, 24 h or 48 h after scratching. Data were analyzed using ImageJ software.

Annexin V-FITC double-staining. After growing till about 80% density within the 100-mm dishes, A549 cells were treated with 24-h DMSO or CUR5g (10 μM), followed by cell collection and staining using FITC apoptosis detection kit I in line with specific instructions. Data acquisition and analysis using flow cytometry.

Animal experiments. All in vivo experimental protocols were carried out following Guide for the Care and Use of Laboratory Animals released by US National Institutes of Health (NIH Publication No. 85-23, revised 1996). Each experiment gained approval from Animal Care Committee of Laboratory Animal Center of Zhengzhou University. (Approval no. ZZU-LAC20211015 [17]). This study obtained BALB/c nude mice (4-week-old) in Beijing Vital River Laboratory Animal Technology Co., Lt and maintained them within the specific pathogen-free (SPF) environment at Laboratory Animal Center from School of Medical Sciences of Zhengzhou University (Henan Province, China), 1 × 10^6 A549 cells were subcutaneously injected into the right scapula of each nude mouse. At 14-day post-implantation of A549 cells, palpable tumors were observed in each mouse. Later, mice were randomized into 4 groups (n = 4 or 5 each group). CUR5g (40 mg/kg), cisplatin (1 mg/kg), CUR5g (40 mg/kg) and cisplatin (1 mg/kg) were injected via caudal vein every 2 days for up to 15 days. Control mice were given injection of the same concentration of DMSO. A micrometer was employed for measuring tumor size at 2-day intervals from the initial injection. This work determined tumor volume by tumor length × (square of width)/2. All animals were sacrificed after the last injection for 48 h, and the tumors and major organs were removed and weighed immediately. Each major organ was subject to embedding in optimal cutting temperature (OCT) compound (Tissue-Tek), followed by slicing in the 7-μm slices using the ultrathin semiautomatic microtome (CM1850, Leica, Wetlar, Germany). For histologic examination, cytossections were subject to H&E staining.

Statistical analysis. Each experiment was carried out twice in triplicate. Average values between two groups were compared by unpaired Student’s t test, while multiple groups were compared by ANOVA. Statistical significance was assigned when *p < 0.05 or **p < 0.01 with SPSS17.0. (Almonk, New York, USA). Results were represented by mean ±SD.

DATA AVAILABILITY

The datasets used and analyzed during the current study are available from the corresponding author upon reasonable request.

REFERENCES

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.
2. Herbst RS, Mok TS, Belani CP, Boffa DJ, Brody O, Crowley J, et al. Non-small cell lung cancer. N Engl J Med. 2018;378:1855–67.
3. Pan X, Chen Y, Shen Y, Tantai J. Knockdown of TRIM65 inhibits autophagy and apoptosis in A549/DDP cells by regulating miR-138-5p/ATG7. Cell Death Dis. 2019;10:429.
4. Liu G, Pei F, Yang F, Li L, Amin AD, Liu S, et al. Role of autophagy and apoptosis in non-small-cell lung cancer. Int J Mol Sci. 2017;18:367.
5. Shi S, Tan P, Yan B, Gao R, Zhao J, Wang J, et al. ER stress and autophagy are involved in the apoptosis induced by cisplatin in human lung cancer cells. Oncol Rep. 2016;35:2606–14.
6. Wu T, Wang MC, Jing L, Liu ZY, Guo H, Liu Y, et al. Autophagy facilitates lung adenocarcinoma resistance to cisplatin treatment by activation of AMPK/mTOR signaling pathway. Drug Des Dev Ther. 2015;9:6421–31.
7. Shi TT, Yu XX, Yan LJ, Xiao HT. Research progress of hydroxychloroquine and autophagy inhibitors on cancer. Cancer Chemother Pharm. 2017;79:287–94.
8. Lebun JA, LeSaint KT. Brief review of hydrochloroquine and hydroxychloroquine toxicity and management. West J Emerg Med. 2020;21:760–30.
9. Lao Y, Wan G, Liu Z, Wang X, Ruan P, Wu X, et al. The natural compound oblongofolin C inhibits autophagic flux and enhances antitumor efficacy of nutrient deprivation. Autophagy. 2014;10:736–49.
10. Zhou J, Li G, Zhang Y, Shen HM, Hu X, Ming QL, et al. A novel autophagy/mitophagy inhibitor lisinesine sensitizes breast cancer cells to chemotherapy through DNMT1-mediated mitochondrial fission. Autophagy. 2015;11:1259–79.
11. Zhao X, Fang Y, Yang Y, Qin Y, Wu F, Wang T. Elaioiphycin, a novel autophagy inhibitor, exerts antitumor activity as a single agent in ovarian cancer cells. Autophagy. 2015;11:1849–63.
12. Wang K, Liu X, Liu Q, Hu IH, Wei X, Yin T, et al. Hederagenin potentiates cisplatin- and paclitaxel-mediated cytotoxicity by impairing autophagy in lung cancer cells. Cell Death Dis. 2020;11:611.
13. Zhan Y, Wang K, Li Q, Zou Y, Chen B, Gong Q, et al. The novel autophagy inhibitor alpha-hederinem promoted paclitaxel cytotoxicity by increasing reactive oxygen species accumulation in non-small cell lung cancer cells. Int J Mol Sci. 2019;20:3221.
14. Liang Z, Liang Q, Yu J, Miao Y, Chen Z, Qu J, et al. Identification of compound CA-5F as a novel late-stage autophagy inhibitor with potent ant-tumor effect against non-small cell lung cancer. Autophagy. 2019;15:391–406.
15. Shaheri A, Cicero A, Panahi Y, Mohajeri M, Sahelbar A. Curcumin: a naturally occurring autophagy modulator. J Cell Physiol. 2019;234:5643–54.
16. Liu Z, Zhang L, Liu Y, Zhang H, Chen J, Feng G, et al. Identification of compound CB-2 as a novel late-stage autophagy inhibitor exhibits inhibitory potency against A549 cells. Life Sci. 2021;11865.
17. Itakura E, Kish-Hakuca K, Mizushima N. The hairpin-type tail-anchored SNARE syntaxin 17 targets to autophagosomes for fusion with endosomes/lysosomes. Cell 2012;151:1256–69.
18. Jäger S, Bucci C, Tanida I, Ueno T, Kominami E, Saftig P, et al. Role for Rab7 in autophagosome-lysosome fusion through interaction with syntaxin 17. Mol Biol Cell. 2014;125:327–37.
19. Liang C, Lee JS, Inn KS, Gack MU, Li Q, Roberts EA, et al. Beclin1-binding UVRAG targets the class C Vps complex to coordinate autophagosome maturation and endocytic trafficking. Nat Cell Biol. 2008;10:776–87.
20. Shen W, Zhang X, Fu X, Fan J, Luan J, Cao Z, et al. A novel and promising therapeutic approach for NSCLC: recombinant human arginase alone or combined with autophagy inhibitor. Cell Death Dis. 2017;8:e2720.
21. Manic G, Obrist F, Kroemer G, Vitale I, Galluzzi L. Chloroquine and hydroxychloroquine for cancer therapy. Mol Cell Oncol. 2014;6:e29911.
22. Amaravadi RK, Kimmelman AC, Debnath J. Targeting autophagy in cancer: recent advances and future directions. Cancer Discov. 2019;9:1167–81.
23. Chude CL, Amaravadi RK. Targeting autophagy in cancer: update on clinical trials and novel inhibitors. Int J Mol Sci. 2017;18:12179.
24. Ye J, Zheng M. Autophagy trafficking. Adv Exp Med Biol. 2021;1208:67–77.
25. Takáts S, Pirics K, Nagy P, Varga Á, Karpáti M, Hegedüs K, et al. Interaction of the HOPS complex with Syntaxin 17 mediates autophagosome clearance in Drosophila. Mol Biol Cell. 2014;25:1338–54.
26. Hegedüs K, Takáts S, Kovács AL, Juhász G. Evolutionarily conserved role and physiological relevance of a STX17/Syx17 (syntaxin 17)-containing SNARE complex in autophagosome fusion with endosomes and lysosomes. Autophagy. 2013;9:1642–6.
27. Wang Q, Xue L, Zhang X, Bu Z, Zhu X, Lai D. Autophagy protects ovarian cancer-associated fibroblasts against oxidative stress. Cell Cycle. 2016;15:1376–85.
28. Liu S, Cai X, Xia L, Jiang C, Chen P, Wang X, et al. Chloroquine exerts antitumor effects on NB4 acute promyelocytic leukemia cells and functions synergistically with arsenic trioxide. Oncol Lett. 2018;15:2024–30.
29. Plaimee P, Weerapreeyakul N, Barusrix SU, Johns NP. Melatonin potentiates cisplatin-induced apoptosis and cell cycle arrest in human lung adenocarcinoma cells. Cell Prolif. 2015;48:E77–87.
30. Sarin N, Engel F, Kalayda GV, Mannewitz M, Cinatl J Jr, Rothweiler F, et al. Cisplatin resistance in non-small cell lung cancer cells is associated with an abrogation of cisplatin-induced G2/M cell cycle arrest. PloS One. 2017;12:e0181081.
31. Liu D, Yang Y, Liu Q, Wang J. Inhibition of autophagy by 3-MA potentiates cisplatin-induced apoptosis in esophageal squamous cell carcinoma cells. Med Oncol. 2011;28:105–11.
38. Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins: Identification by morphologic and immunologic criteria. J Clin Invest. 1973;52:2745–56.

ACKNOWLEDGEMENTS
We would like to acknowledge the National Natural Science Foundation of China and the Natural Science Innovation Fund of Henan University of Technology. We thank Youli Jian for kindly providing the plasmids Rab7-Q67L and Rab7-T22N, Jing Liu for kindly providing U87 and HEK293T, Haiying Li for kindly providing HBMECs.

AUTHOR CONTRIBUTIONS
LZ performed the study concept and design; JXC, YPS, BWW, PCY, GCS, XTL, PFQ, YMG, FFS, ZRL, and LZ performed the experiments, data analysis, and interpretation; LZ and JXC wrote the manuscript and assembled the figures; LZ provided facilities and material support; All authors read and approved the final submitted paper.

FUNDING
This work was funded by the National Natural Science Foundation of China (no. 32070742) and the Natural Science Innovation Fund of Henan University of Technology (no. 2021ZKCJ16).

COMPETING INTERESTS
The inhibitory effect of CUR5g on autophagy of A549 cells has been applied for China Creative Patent (Application no. CN 202110528508.9).

ETHICS
All animal experiments were performed in accordance with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication no. 85-23, revised 1996) and was approved by the Animal Care Committee of Laboratory Animal Center of Zhengzhou University (approval no. ZZU-LAC20211015).

ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41420-022-01217-9.

Correspondence and requests for materials should be addressed to Lu Zhang.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022